In a first experiment, we estimated the false positive rate for detection of known TP53 mutations as cataloged in the Catalogue of Somatic Mutations in Cancer (COSMIC) database38 in four sequencing runs based on a TP53 amplicon covering one, multiple or all TP53 exons, amplified from control cfDNA samples from individuals without cancer (Fig. 4). This evidence concerns the gene TP53 and cancer.